Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Astrocytoma × Clear all

Phase

Phase 1 28 Phase 2 16 Phase 1/2 15 Phase 3 11 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

OTHER 1 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Neoplasms 21 Breast Neoplasms 19 Neoplasm Metastasis 18 Prostatic Neoplasms 15 Stomach Neoplasms 14 Colorectal Neoplasms 14 Recurrence 13 Squamous Cell Carcinoma of Head and Neck 10 Pancreatic Neoplasms 10 Ovarian Neoplasms 10 Lung Neoplasms 10 Head and Neck Neoplasms 10 Carcinoma, Hepatocellular 10 Myasthenia Gravis 9 Urinary Bladder Neoplasms 8 Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Melanoma 7 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 6 Cholangiocarcinoma 6 Small Cell Lung Carcinoma 5 Lymphoma, Follicular 5 Liver Neoplasms 5 Glioblastoma 5 Colonic Neoplasms 5 Carcinoma, Transitional Cell 5 Biliary Tract Neoplasms 5

Interventions

vocimagene amiretrorepvec 1 Temozolomide 1 Lomustine 1 Flucytosine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡